Evidence map›Paper›PMID 36644007›Full record

ArticleSynthesis2023

Building Chemical Probes Based on the Natural Products YM-254890 and FR900359: Advances toward Scalability.

Matthew R Medcalf, Ruby L Krueger, Zach T Medcalf, Peter A Rosston, Yu Zhu, Kevin M Kaltenbronn, Kendall J Blumer, Kevin D Moeller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Synthesis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Building Block Approach for the Total Synthesis of YM-385781.European journal of organic chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matthew R MedcalfDepartment of Chemistry, Washington University, St. Louis, MO, USA.
Ruby L KruegerDepartment of Chemistry, Washington University, St. Louis, MO, USA.
Zach T MedcalfDepartment of Chemistry, Washington University, St. Louis, MO, USA.
Peter A RosstonDepartment of Chemistry, Washington University, St. Louis, MO, USA.
Yu ZhuDepartment of Chemistry, Washington University, St. Louis, MO, USA.
Kevin M KaltenbronnDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Kendall J BlumerDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Kevin D MoellerDepartment of Chemistry, Washington University, St. Louis, MO, USA.

Funding

PHARMACOLOGICAL TARGETING OF GALPHA SUBUNITS IN DISEASER01GM124093 · NIGMS · WASHINGTON UNIVERSITY · PI BLUMER, KENDALL J, MOELLER, KEVIN DAVID · 2017 to 2024
$3.6M
NIGMS NIH HHS R01 GM124093
6 · The paper itself

Abstract

The biological activity of natural products YM-254890 (YM) and FR900359 (FR) has led to significant interest in both their synthesis and the construction of more simplified analogs. While the simplified analogs lose much of the potency of the natural products, they are of interest in their own right, and their synthesis has revealed synthetic barriers to the family of molecules that need to be addressed if a scalable synthesis of YM and FR analogs is to be constructed. In the work described here, a synthetic route to simplified analogs of YM is examined and strategies for circumventing some of the challenges inherent to constructing the molecules are forwarded.

Indexed as

analogsFR900359scalable synthesisYM-254890

Identifiers

PMID36644007
PMCPMC9838186

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.